Catheter-Mediated Selective Thrombolysis and Anticoagulant Therapy for Deep Vein Thrombosis: Analysis of Efficacy, Safety and Clinical Outcomes

Background. Deep vein thrombosis (DVT) is an important component of venous thromboembolism and can lead to pulmonary embolism with high morbidity and mortality. Anticoagulant therapy alone (ACA) and catheter-mediated thrombolysis (CDT) are commonly used strategies for the management of DVT. Although CDT has been reported to be effective in reducing the risk of postthrombotic syndrome (PTS), it remains unclear in which patient groups it should be preferred due to the risk of bleeding.Methods. This retrospective study included 175 patients diagnosed with DVT between 2015 and 2024 (98 ACA, 77 CDT). Patients with a diagnosis of proximal DVT, aged ≥18 years and with at least 30 days of follow-up data were included. The primary endpoint was 30-day mortality and secondary endpoints were length of hospitalization, pulmonary embolism and bleeding complications. Results. The CDT group was superior to ACA in thrombus clearance rates, especially in iliac vein thrombosis (97.7% vs. 78%, p=0.003). Clinical symptoms improved faster in the CDT group, but total hospitalization was longer. There were no significant differences in bleeding complications and mortality rates between the two groups.Conclusion. The optimal approach to DVT treatment should be based on the patient's individual risk factors. Although CDT provides a higher thrombus clearance rate, especially in iliac vein thrombosis, it may not be suitable for all patients. Future large-scale studies will contribute to a better understanding of the long-term outcomes of interventional therapies.